 Currently, neuraminidase inhibitors (NAIs) are the most frequently prescribed antivirals because they are effective against both influenza A and B.However, antiviral resistance is known to develop if mutations to the neuraminidase proteins prevent NAI binding.This was seen in the H257Y mutation, which was responsible for oseltamivir resistance to H1N1 strains in 2009.